Patent ID: 9675692
Date: 2017-06-13
CPC Classifications: A61K,A61P

Claim:
1. A pharmaceutical formulation consisting of (a) 25 mg/mL±3.75 mg/mL of an anti-Dll4 antibody comprising the HCVD of SEQ ID NO: 1 and the LCVD of SEQ ID NO: 5, (b) 10 mM±3 mM phosphate, pH 6±0.5, (c) 0.2%±0.03% polysorbate 20, (d) 150 mM±22.5 mM sodium chloride, and (e) 10%±1.5% sucrose, in water wherein the antibody a molecular weight of about 150 kDa; and about 82% to about 87% of the antibodies are fucosylated.